Home › Companies › Atea Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Atea Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-22 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Atea Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Atea Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-22 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Jerome Adams, MD, MPH | 28,798,012 | -- | -- | 22,275,665 | 8,669,142 | Majority: yes |
| Elect Director: Howard Berman, PhD | 44,466,627 | -- | -- | 6,607,050 | 8,669,142 | Majority: yes |
| Elect Director: Barbara Duncan | 43,697,098 | -- | -- | 7,376,579 | 8,669,142 | Majority: yes |
| Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. | 58,894,207 | 783,081 | 65,531 | -- | 0 | Majority: yes |
| Proposal 3: Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | 47,452,759 | 2,977,290 | 643,628 | -- | 8,669,142 | Majority: yes |
Source: Atea Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-22 — read the filing on EDGAR.
Each item below shows how the 133 asset managers that disclosed a Atea Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 5 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Atea Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”): 47,452,759 for, 2,977,290 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 80,027,099 outstanding shares: 59% for, 4% against (63% of the company cast a for/against vote).
The 133 asset managers below cast 97% of the shares they voted on this item FOR (40,534,771 for, 1,130,316 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 18,860,057 | 0 | 0 | 0 | For |
| BlackRock | 5,125,739 | 12,745 | 0 | 0 | For |
| Vanguard | 4,285,840 | 3,294 | 3 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 2,210,339 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,731,410 | 0 | 0 | 0 | For |
| Charles Schwab | 1,193,315 | 0 | 0 | 0 | For |
| State Street | 1,114,600 | 19,700 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 819,128 | 0 | 0 | 0 | For |
| Two Sigma | 781,929 | 0 | 0 | 0 | For |
| Renaissance | 530,433 | 0 | 0 | 0 | For |
| Northern Trust | 467,226 | 2,156 | 0 | 0 | For |
| American Century | 0 | 342,068 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 260,551 | 0 | 0 | 0 | For |
| DE Shaw | 251,664 | 0 | 0 | 0 | For |
| Nuveen | 243,103 | 0 | 0 | 0 | For |
| TIAA | 241,505 | 0 | 0 | 0 | For |
| T. Rowe Price | 208,737 | 0 | 0 | 0 | For |
| Dimensional | 0 | 185,118 | 0 | 0 | Against |
| Equitable | 184,775 | 0 | 0 | 0 | For |
| JPMorgan | 157,732 | 0 | 0 | 0 | For |
| Goldman Sachs | 156,752 | 0 | 0 | 0 | For |
| Wellington | 0 | 143,567 | 0 | 0 | Against |
| AllianceBernstein | 121,320 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 114,880 | 0 | 0 | 0 | For |
| Lincoln Financial | 105,419 | 4,025 | 0 | 0 | For |
Showing the 25 largest of 133 asset managers. See all 133 in the interactive database.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Barbara Duncan”): 43,697,098 for, 7,376,579 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 80,027,099 outstanding shares: 54.6% for, 9% withheld (64% of the company cast a for/withheld vote).
The 46 asset managers below cast 100% of the shares they voted on this item FOR (15,171,378 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,910,099 | 0 | 92 | 0 | For |
| Vanguard | 3,772,340 | 0 | 9,986 | 0 | For |
| BlackRock | 2,883,978 | 0 | 0 | 0 | For |
| Charles Schwab | 596,519 | 0 | 0 | 0 | For |
| TIAA | 241,505 | 0 | 0 | 0 | For |
| Equitable | 109,185 | 0 | 75,590 | 0 | For |
| American Century | 0 | 0 | 171,034 | 0 | Abstain |
| JPMorgan | 157,732 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 144,764 | 0 | Abstain |
| Lincoln Financial | 105,419 | 0 | 4,025 | 0 | For |
| Goldman Sachs | 0 | 0 | 107,065 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 105,742 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 73,473 | 0 | Abstain |
| Brighthouse | 34,841 | 0 | 38,554 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 70,000 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 68,110 | 0 | 0 | 0 | For |
| T. Rowe Price | 65,641 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 64,063 | 0 | Abstain |
| EA Series Trust | 49,364 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 48,664 | 0 | Abstain |
| Voya | 0 | 0 | 43,138 | 0 | Abstain |
| Global X | 0 | 0 | 30,344 | 0 | Abstain |
| Bridge Builder Trust | 30,304 | 0 | 0 | 0 | For |
| Pacific Life | 27,265 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 15,000 | 0 | Abstain |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Combines 5 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Howard Berman, PhD”): 44,466,627 for, 6,607,050 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 80,027,099 outstanding shares: 56% for, 8% withheld (64% of the company cast a for/withheld vote).
The 46 asset managers below cast 100% of the shares they voted on this item FOR (15,489,659 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,910,099 | 0 | 92 | 0 | For |
| Vanguard | 3,782,306 | 0 | 20 | 0 | For |
| BlackRock | 2,883,978 | 0 | 0 | 0 | For |
| Charles Schwab | 596,519 | 0 | 0 | 0 | For |
| TIAA | 241,505 | 0 | 0 | 0 | For |
| Equitable | 109,185 | 0 | 75,590 | 0 | For |
| American Century | 0 | 0 | 171,034 | 0 | Abstain |
| JPMorgan | 157,732 | 0 | 0 | 0 | For |
| Northern Trust | 144,764 | 0 | 0 | 0 | For |
| Lincoln Financial | 105,419 | 0 | 4,025 | 0 | For |
| Goldman Sachs | 107,065 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 105,742 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 73,473 | 0 | Abstain |
| Brighthouse | 34,841 | 0 | 38,554 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 70,000 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 68,110 | 0 | 0 | 0 | For |
| T. Rowe Price | 65,641 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 64,063 | 0 | Abstain |
| EA Series Trust | 49,364 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 48,664 | 0 | Abstain |
| Voya | 0 | 0 | 43,138 | 0 | Abstain |
| Global X | 30,344 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,304 | 0 | 0 | 0 | For |
| Pacific Life | 27,265 | 0 | 0 | 0 | For |
| SEI | 15,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Combines 4 wordings of this item as funds reported it.
56% Majority: yes · of votes cast
Atea Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jerome Adams, MD, MPH”): 28,798,012 for, 22,275,665 withheld, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 80,027,099 outstanding shares: 36% for, 28% withheld (64% of the company cast a for/withheld vote).
The 46 asset managers below cast 100% of the shares they voted on this item FOR (7,967,190 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 1,475,271 | 0 | 5,434,920 | 0 | Abstain |
| Vanguard | 3,772,290 | 0 | 10,036 | 0 | For |
| BlackRock | 2,092,540 | 0 | 791,438 | 0 | For |
| Charles Schwab | 0 | 0 | 596,519 | 0 | Abstain |
| TIAA | 0 | 0 | 241,505 | 0 | Abstain |
| Equitable | 109,185 | 0 | 75,590 | 0 | For |
| American Century | 0 | 0 | 171,034 | 0 | Abstain |
| JPMorgan | 157,732 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 144,764 | 0 | Abstain |
| Lincoln Financial | 105,419 | 0 | 4,025 | 0 | For |
| Goldman Sachs | 0 | 0 | 107,065 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 105,742 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 73,473 | 0 | Abstain |
| Brighthouse | 34,841 | 0 | 38,554 | 0 | Abstain |
| Delaware/Macquarie | 0 | 0 | 70,000 | 0 | Abstain |
| MASTER INVESTMENT PORTFOLIO | 0 | 0 | 68,110 | 0 | Abstain |
| T. Rowe Price | 0 | 0 | 65,641 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 64,063 | 0 | Abstain |
| EA Series Trust | 49,364 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 48,664 | 0 | Abstain |
| Voya | 0 | 0 | 43,138 | 0 | Abstain |
| Global X | 0 | 0 | 30,344 | 0 | Abstain |
| Bridge Builder Trust | 30,304 | 0 | 0 | 0 | For |
| Pacific Life | 27,265 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 15,000 | 0 | Abstain |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Atea Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026.”): 58,894,207 for, 783,081 against, per its Form 8-K filed 2026-06-22 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 80,027,099 outstanding shares: 74% for, 1.0% against (75% of the company cast a for/against vote).
The 46 asset managers below cast 99.9% of the shares they voted on this item FOR (16,160,961 for, 3 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 6,910,191 | 0 | 0 | 0 | For |
| Vanguard | 3,782,323 | 3 | 0 | 0 | For |
| BlackRock | 2,883,978 | 0 | 0 | 0 | For |
| Charles Schwab | 596,519 | 0 | 0 | 0 | For |
| TIAA | 241,505 | 0 | 0 | 0 | For |
| Equitable | 184,775 | 0 | 0 | 0 | For |
| American Century | 171,034 | 0 | 0 | 0 | For |
| JPMorgan | 157,732 | 0 | 0 | 0 | For |
| Northern Trust | 144,764 | 0 | 0 | 0 | For |
| Lincoln Financial | 109,444 | 0 | 0 | 0 | For |
| Goldman Sachs | 107,065 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 105,742 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 73,473 | 0 | 0 | 0 | For |
| Brighthouse | 66,198 | 0 | 7,197 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 68,110 | 0 | 0 | 0 | For |
| T. Rowe Price | 65,641 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 64,063 | 0 | 0 | 0 | For |
| EA Series Trust | 49,364 | 0 | 0 | 0 | For |
| Dimensional | 48,664 | 0 | 0 | 0 | For |
| Voya | 43,138 | 0 | 0 | 0 | For |
| Global X | 30,344 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 30,304 | 0 | 0 | 0 | For |
| Pacific Life | 27,265 | 0 | 0 | 0 | For |
| SEI | 15,000 | 0 | 0 | 0 | For |
Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.
Ranked by the number of Atea Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 80,027,099 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 23.57% |
| 2 | BlackRock | 6.42% |
| 3 | Vanguard | 5.36% |
| 4 | Bain Capital Life Sciences Investors, LLC | 2.76% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.16% |
| 6 | Charles Schwab | 1.49% |
| 7 | State Street | 1.42% |
| 8 | ACADIAN ASSET MANAGEMENT LLC | 1.02% |
| 9 | Two Sigma | 0.98% |
| 10 | Renaissance | 0.66% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 14.93% | 13F |
| BlackRock | 10.54% | 13F |
| BML Investment Partners, L.P. | 9.36% | 13G |
| Vanguard Group | 5.28% | 13F |
| Two Sigma | 2.33% | 13F |
| Geode Capital | 2.18% | 13F |
| State Street | 2.12% | 13F |
| Dimensional Fund Advisors | 1.57% | 13F |
| Renaissance Technologies | 1.46% | 13F |
| JPMorgan Chase | 1.17% | 13F |
Percentages above are of 80,027,099 shares outstanding, as reported by Atea Pharmaceuticals, Inc. on its Form 10-Q dated 2026-05-11 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Atea Pharmaceuticals, Inc.’s 10-Q dated 2026-05-11. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Atea Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-18, in the 2025-2026 proxy season, 133 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 903 separate fund positions. On the most widely held item on that ballot — Approval, on an advisory (non- binding) basis, of the compensation of the named executive… — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Atea Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-22.
Atea Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).